

BRCAssure[®]

BRCA1 and *BRCA2* analysis.

Because knowledge is a powerful tool.



HEREDITARY BREAST AND OVARIAN CANCER

Patients with **BRCA** mutations are at increased risk for breast, ovarian, and other cancers.

- Mutations in *BRCA1* and *BRCA2* account for the vast majority of families with Hereditary Breast and Ovarian Cancer Syndrome (HBOC).¹
- The estimated lifetime risk of breast cancer in women with *BRCA1* mutations is 46-87%; for *BRCA2*, the risk is 38-84%.²
- The risk of ovarian cancer is 39-63% for a woman with *BRCA1* and 16.5-27% with *BRCA2*.²
- Both men and women with mutations in *BRCA1/2* may also be at increased risk of other cancers, including pancreatic, prostate, and melanoma.²


1 in 40


Approximately **1 in 40** Ashkenazi Jewish individuals carries one of three founder mutations.²

1 in 400

The overall prevalence of *BRCA1* and *BRCA2* mutations in the general population is estimated at **1 in 400**² and varies with ethnicity.

Estimated lifetime cancer risk for individuals with *BRCA1* and *BRCA2* mutations²





Knowing your patient's BRCA mutation status may assist in developing tailored prevention and treatment strategies.

NCCN® and ACOG recognize the importance of testing for *BRCA1* and *BRCA2* mutation.

INDICATIONS FOR BRCAssure TESTING^{1,3}

Consider BRCAssure testing for your patients if their personal or family history has one of the following indications:

- Breast cancer diagnosed at age 45 or younger
- Ovarian cancer
- Both breast and ovarian cancer
- Two primary breast cancers, the first diagnosed at age 50 or younger
- Male breast cancer
- Triple-negative breast cancer diagnosed ≤60 years of age
- Exocrine Pancreatic cancer
- Metastatic or intraductal prostate cancer
- A previously identified *BRCA1* or *BRCA2* mutation in the family
- Ashkenazi Jewish ancestry; or a relative with breast, pancreatic, or high-grade prostate cancer
- Two or more relatives with breast cancer, one under age 50
- Three or more relatives with breast cancer at any age

Notes: "Breast cancer" includes both invasive and ductal carcinoma in situ (DCIS). "Ovarian cancer" includes epithelial ovarian cancer, fallopian tube and primary peritoneal cancer.³ Complete Guidelines may be found at www.nccn.org; www.ACOG.org.

NCCN® is a trademark owned by the National Comprehensive Cancer Network, Inc.

GENETIC COUNSELING IS HIGHLY RECOMMENDED WHEN BRCA TESTING IS OFFERED AND AFTER RESULTS ARE PROVIDED¹

Integrated Genetics provides nationwide access to genetic counseling service expertise through our telegenetic counseling program and provides convenience to patients with online scheduling. Your patients can quickly schedule a genetic counseling appointment at www.integratedgenetics.com/genetic-counseling.



Call **855-GC-CALLS (855-422-2557)** to learn more about our exceptional services or visit www.integratedgenetics.com/genetic-counseling.

Toll-free (within the US) at
800.848.4436
www.integratedgenetics.com

3400 Computer Drive
 Westborough Massachusetts 01581



Integrated Genetics is a brand used by Esoterix Genetic Laboratories, LLC, a wholly owned subsidiary of Laboratory Corporation of America® Holdings.

Test name	Test code
BRCAssure: Comprehensive <i>BRCA1/2</i> Analysis	485030
BRCAssure: Ashkenazi Jewish Panel	485097
BRCAssure: <i>BRCA1</i> Targeted Analysis	485066
BRCAssure: <i>BRCA2</i> Targeted Analysis	485081
BRCAssure: <i>BRCA1/2</i> Deletion/Duplication Analysis	485050
Specimen requirements: 7 mL whole blood Lavender-top (EDTA) tube OR 2 mL saliva Oragene®-Dx saliva collection kit	



A continuity of care, pioneering science, professional service

We provide the scientific expertise you need, and the customer experience patients want.



RAPID RESULTS

Samples have a typical turnaround time of 3 weeks after a test arrives at our lab.



EXTENSIVE MANAGED CARE CONTRACTS

Help patients maximize their benefits. Where applicable, Integrated Genetics can initiate prior authorization for Hereditary Cancer testing with or without a specimen.



CONVENIENT BLOOD DRAWS

We have a nationwide network of patient service centers, allowing for convenient access to sample collection. Visit www.LabCorp.com to find your nearest location.



CONFIRMATORY TESTING FOR DIRECT TO CONSUMER RESULTS

Our Hereditary Cancer portfolio provides the testing options needed to confirm patient results from direct to consumer genetics laboratories as appropriate.



WOMEN'S HEALTH AND WELLNESS

As a subsidiary of LabCorp, Integrated Genetics provides access to a complete women's health offering featuring a full range of testing and services that support the continuity of care for your patients through a single laboratory.

REFERENCES

1. American College of Obstetricians and Gynecologists. Hereditary Breast and Ovarian Cancer Syndrome. ACOG Practice Bulletin. No. 182. Obstet Gynecol. 2017; Sep;130(3):e-110-e126.
2. Petrucelli, N et al. *BRCA1* and *BRCA2* Hereditary Breast and Ovarian Cancer. *Gene Reviews*. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1247>. Accessed July 24, 2018.
3. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. NCCN Guidelines Version 1.2020. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed January 3, 2020.